Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)

ClinicalTrials.gov ID: NCT04343248

Public ClinicalTrials.gov record NCT04343248. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)

Study identification

NCT ID
NCT04343248
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Romark Laboratories L.C.
Industry
Enrollment
190 participants

Conditions and interventions

Interventions

  • Nitazoxanide Drug
  • Placebo Drug
  • Vitamin Super B-Complex Dietary Supplement

Drug · Dietary Supplement

Eligibility (public fields only)

Age range
55 Years to 120 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 11, 2020
Primary completion
Jan 31, 2021
Completion
Jan 31, 2021
Last update posted
Jul 7, 2024

2020 – 2021

United States locations

U.S. sites
4
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
The Chappel Group Research Kissimmee Florida 34744
Clinical Trial Specialists, Inc. Acworth Georgia 30101
Centex Studies, Inc. Lake Charles Louisiana 70601
Centex Studies, Inc. Houston Texas 77058

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04343248, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 7, 2024 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04343248 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →